CDK Inhibitor

Sinigrin (Standard) (Allyl-glucosinolate (Standard)) is the analytical standard of Sinigrin (HY-N0404). This product is intended for research and analytical applications. Sinigrin (Allyl-glucosinolate) is an orally active glucosinolate found in cruciferous plants. Sinigrin possesses multiple activities such as anti-cancer, antibacterial, antifungal, anti-inflammatory, antioxidant, and inhibition of fat synthesis. Sinigrin can be used in the research of tumors, inflammatory, and metabolic diseases.

Hsp90-IN-46 is a Hsp90 inhibitor. Hsp90-IN-46 exhibits broad-spectrum antiproliferative activity against tumor cell lines. Hsp90-IN-46 inhibits breast cancer cell proliferation by reducing colony formation and downregulating the proliferation marker Ki-67. Hsp90-IN-46 inhibits Hsp90 and its ATPase activity, downregulates the downstream substrate oncoproteins HER2 and CDK4, and moderately induces the heat shock response. Hsp90-IN-46 shows significant antitumor activity in a mouse model of triple-negative breast cancer tumor xenografts. Hsp90-IN-46 can be used for research on various cancers including triple-negative breast cancer, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer.

PHA-690509 is an anti-ZikV compound that inhibits ZikV replication. PHA-690509 is also a CDK inhibitor, and inhibits caspase-3 activity.

CDK9-IN-52 is a CDK9 inhibitor. CDK9-IN-52 exhibits antiproliferative activity against cancer cells. CDK9-IN-52 can be used in studies related to lung cancer, cervical cancer, and breast cancer.

CDK2-IN-62 is a predicted CDK2 inhibitor. CDK2-IN-62 induces apoptosis in breast cancer cells and reduces their colony-forming ability. CDK2-IN-62 can be used for the research of breast cancer, ovarian cancer and colorectal cancer.

KDM1/CDK1-IN-1 (compound 4) is a potent KDM1 and CDK1 inhibitor, with IC₅₀ values of 0.096 and 0.078 μM, respectively.KDM1/CDK1-IN-1 induces cell cycle arrest at G2/M phase and apoptosis in HOP-92 cells. KDM1/CDK1-IN-1 exhibits potent cytotoxic activity against the CCRF-CEM, HOP-92 and Hep-G2 cells, with IC₅₀ values of 16.34, 3.45 and 7.79 μM, respectively.

CDK7-IN-12 is a potent inhibitor of CDK7. CDK7-IN-12 plays a key role in transcriptional regulation and cell cycle regulation. CDK7-IN-12 effectively inhibit malignant tumor proliferation in vitro and in vivo. CDK7-IN-12 has the potential for the research of cancer disease (extracted from patent WO2021249417A1, compound 43).

CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC₅₀ value of 6.0 nM. CDK2-IN-43 can be used in the research of the anti-cancer field.

CDK2-IN-36 (compound1) is a CDK2 inhibitor with anticancer activity.

CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12/13, with IC₅₀ values of 15.5 nM and 12.2 nM for CDK12 and CDK13, respectively. CDK12/13-IN-2 can inhibit the proliferation of breast cancer cells and can be used in the research of triple-negative breast cancer.

Aristolochic acid D (Standard) (Aristolochic acid-IVa (Standard)) is the analytical standard of Aristolochic acid D (HY-N1465). This product is intended for research and analytical applications. Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC₅₀: 4.673 μM) and CDK2 (IC₅₀: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases.

ARUK2010489 (Compound 23) is a potent, selective and brain-penetrant NUAK1 inhibitor with a pIC₅₀ of 8.7. ARUK2010489 also inhibits CDK2, CDK4 and CDK6 activity, with inhibitory rate of 7%, 39% and 26% at 1 μM. ARUK2010489 can be used for the research of neurological disease, such as Alzheimer’s disease (AD).

CDK2-IN-18 (compound 8q) is a potent inhibitor of CDK2/E and CDK4/D1, with IC₅₀s of 8 nM and 46 nM, respectively. CDK2-IN-18 inhibits the proliferation of tumor cells.

Cdk9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK2/9-IN-1 (compound 20a) is an orally active dual inhibitor of CDK2 and CDK9 with IC₅₀ values are 0.004 μM and 0.009 μM respectively. CDK2/9-IN-1 induces apoptosis by regulating G2/M cell cycle arrest. CDK2/9-IN-1 has antitumor activity.

EGFR/CDK2-IN-5 is a potent dual EGFR and CDK2 inhibitor with IC₅₀s of 17.30 and 212.10 nM, respectively. EGFR/CDK2-IN-5 also inhibits EGFR^T790M with an IC₅₀ of 123.8 nM. EGFR/CDK2-IN-5 exhibits potent anticancer activity. EGFR/CDK2-IN-5 induces G1 and S cell cycle arrest and apoptosis, accompanied by increased levels of caspase-3/9 and Bax, as well as decreased Bcl-2 levels. EGFR/CDK2-IN-5 can be used for the research of cancers, such as lung cancer, breast cancer, and leukemia.

CDK-IN-15 (Compound 456) is a potent Cyclin A inhibitor, with an IC₅₀ of 0.14 μM.

Cdk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research.

Tacaciclib is a CDK inhibitor, antineoplastic effect.